This company has been marked as potentially delisted and may not be actively trading. Miragen Therapeutics (MGEN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MGEN vs. OPGN, NPCE, TBRG, CADL, LFMD, NATR, TCMD, CLPT, SCPH, and BWAYShould you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include OpGen (OPGN), NeuroPace (NPCE), TruBridge (TBRG), Candel Therapeutics (CADL), LifeMD (LFMD), Nature's Sunshine Products (NATR), Tactile Systems Technology (TCMD), ClearPoint Neuro (CLPT), scPharmaceuticals (SCPH), and Brainsway (BWAY). These companies are all part of the "medical" sector. Miragen Therapeutics vs. Its Competitors OpGen NeuroPace TruBridge Candel Therapeutics LifeMD Nature's Sunshine Products Tactile Systems Technology ClearPoint Neuro scPharmaceuticals Brainsway OpGen (NASDAQ:OPGN) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership. Which has better earnings & valuation, OPGN or MGEN? OpGen has higher earnings, but lower revenue than Miragen Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpGen$2.67M0.00-$32.67MN/AN/AMiragen Therapeutics$4.46M16.53-$41.87M-$20.09-0.94 Does the media favor OPGN or MGEN? In the previous week, OpGen had 1 more articles in the media than Miragen Therapeutics. MarketBeat recorded 1 mentions for OpGen and 0 mentions for Miragen Therapeutics. OpGen's average media sentiment score of 1.00 beat Miragen Therapeutics' score of 0.00 indicating that OpGen is being referred to more favorably in the media. Company Overall Sentiment OpGen Positive Miragen Therapeutics Neutral Do insiders and institutionals believe in OPGN or MGEN? 2.7% of OpGen shares are held by institutional investors. 43.8% of OpGen shares are held by company insiders. Comparatively, 1.1% of Miragen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, OPGN or MGEN? OpGen has a beta of -1.77, indicating that its stock price is 277% less volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Is OPGN or MGEN more profitable? OpGen has a net margin of -1,140.36% compared to Miragen Therapeutics' net margin of -1,393.50%. OpGen's return on equity of 0.00% beat Miragen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OpGen-1,140.36% N/A -287.58% Miragen Therapeutics -1,393.50%-141.66%-88.74% SummaryOpGen beats Miragen Therapeutics on 7 of the 10 factors compared between the two stocks. Get Miragen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGEN vs. The Competition Export to ExcelMetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.74M$1.23M$5.87B$10.14BDividend YieldN/AN/A5.68%4.59%P/E Ratio-1.77N/A74.5225.93Price / Sales16.531.83548.33126.97Price / CashN/AN/A37.5660.44Price / Book2.780.1112.166.29Net Income-$41.87M-$22.69M$3.28B$270.77M Miragen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGENMiragen TherapeuticsN/A$18.87-4.0%N/A-0.8%$73.74M$4.46M-1.7745High Trading VolumeOPGNOpGenN/AN/AN/AN/A$1K$2.67M0.00100Positive NewsShort Interest ↓NPCENeuroPace3.2079 of 5 stars$9.04-1.1%$16.60+83.6%+36.4%$298.71M$79.91M-10.75170Positive NewsTBRGTruBridge1.9628 of 5 stars$19.96-0.1%$21.25+6.5%+68.1%$298.32M$339.17M-23.663,200Positive NewsCADLCandel Therapeutics2.3466 of 5 stars$5.40-7.8%$20.00+270.4%-27.1%$297.34M$120K-7.8560LFMDLifeMD3.4519 of 5 stars$6.27+1.6%$13.17+110.0%+10.9%$297.09M$212.45M-29.83230Trending NewsInsider TradeNATRNature's Sunshine Products3.3654 of 5 stars$16.85+0.3%$19.67+16.7%+28.0%$297.08M$460.82M22.76850Positive NewsTCMDTactile Systems Technology2.2843 of 5 stars$13.29-1.2%$13.50+1.6%+2.0%$296.30M$292.98M21.441,037Positive NewsCLPTClearPoint Neuro1.9187 of 5 stars$10.35-0.7%$19.67+90.0%-13.9%$294.99M$31.39M-12.81110Positive NewsAnalyst UpgradeSCPHscPharmaceuticals4.5104 of 5 stars$5.53+0.3%$7.78+40.9%+6.0%$294.48M$36.33M-3.0530Short Interest ↓BWAYBrainsway3.4272 of 5 stars$15.56+2.1%$18.00+15.7%+95.9%$294.08M$41.02M59.85120Short Interest ↓ Related Companies and Tools Related Companies OpGen Alternatives NeuroPace Alternatives TruBridge Alternatives Candel Therapeutics Alternatives LifeMD Alternatives Nature's Sunshine Products Alternatives Tactile Systems Technology Alternatives ClearPoint Neuro Alternatives scPharmaceuticals Alternatives Brainsway Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGEN) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
